ACCESS Newswire

GeneTex, Inc.

Share
GeneTex Launches PD-L1 Antibody Comprehensively Validated by MS Validated Antibodies GmbH for Immunohistochemistry

IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
PD-L1 Antibody [HL1041] IHC



The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.

Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."

The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."

GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.

Media Contact:

Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com

Contact Information

Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900

SOURCE: GeneTex, Inc.

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Foundations of Neutrinovoltaics: From Shared Knowledge to Shared Future4.9.2025 20:08:00 CEST | Press release

Uniting Mathematics, Artificial Intelligence, and Neutrino Science into a New Energy Paradigm BERLIN, DE / ACCESS Newswire / September 4, 2025 / Every technological leap builds on decades of knowledge. Neutrinovoltaics is no exception. Its foundation lies in the convergence of three intellectual streams, mathematics, artificial intelligence, and neutrino science, that together redefine how electricity can be generated.Holger Thorsten Schubart on Shared Science Celebrating the science that powers neutrinovoltaics The governing formula formalizes this principle: P(t) = η · ∫V Φ_eff(r,t) · σ_eff(E) dV It shows in precise terms how efficiency, flux density, interaction cross-section, and material volume convert invisible radiation into usable current. What once was intangible now has calculable structure. Holger Thorsten Schubart: Visionary and Bridge-Builder At the center of this development stands Holger Thorsten Schubart, mathematician and CEO of Neutrino® Energy Group. For over a decad

LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka4.9.2025 18:50:00 CEST | Press release

AMSTERDAM, NETHERLANDS / ACCESS Newswire / September 4, 2025 / LOLC Advanced Technologies (LOLC AT), a fully owned subsidiary of LOLC Holdings PLC, together with Corsair Group International, headquartered in Amsterdam, has announced a landmark partnership to upgrade and expand LOLC AT's existing waste-to-fuel plant at Kerawalapitiya. This strategic initiative aims to address Sri Lanka's growing plastic and polythene waste challenge. With Sri Lanka generating an estimated 7,000 metric tons of solid waste per day, equating to roughly 2.56 million metric tons per year, a significant portion of which consists of polythene and plastic. Plastic pollution has become one of the nation's most pressing environmental concerns, with much of this waste ends up in overflowing landfills, waterways, and oceans, posing serious threats to ecosystems, public health, and tourism. LOLC AT invested in and commissioned a waste-to-fuel plant in 2023, which it has successfully operated throughout 2024. This fa

MicroVision Appoints Glen DeVos as Chief Executive Officer4.9.2025 15:20:00 CEST | Press release

REDMOND, WA / ACCESS Newswire / September 4, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that the Company's Board of Directors has appointed Glen W. DeVos as Chief Executive Officer and a member of the Company's Board of Directors effective September 30, 2025. Sumit Sharma, the Company's current CEO, will remain in the role through the effective date to ensure a smooth transition. A seasoned executive, DeVos brings more than three decades of leadership in the automotive and industrial technology sectors, delivering advanced technologies and solutions with a focus on autonomy and mobility. Since 1992, DeVos served in various business leadership and technology roles at Aptiv, and its predecessor Delphi Automotive, including as Aptiv's Chief Technology Officer and President of the Advanced Safety and User Experience business unit. His extensive experience developing and driving strategy, le

U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club4.9.2025 13:00:00 CEST | Press release

Global Sports Brand Marks Eighth Year Partnering with the Iconic West Coast Polo Club SANTA BARBARA, CA AND WEST PALM BEACH, FL / ACCESS Newswire / September 4, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly marked a major milestone this past weekend as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, held August 15-31 at the iconic Santa Barbara Polo & Racquet Club. This prestigious tournament, known as the crown jewel of West Coast polo, brought together top-tier talent and record-breaking crowds for one of the sport's most celebrated events.U.S. Polo Assn. Pacific Coast Open Photo Credit: Michelle Lauren For the first time, U.S. Polo Assn. served as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, one of the oldest and most revered polo tournaments in the world, dating back to 1908. As part of a broader partnership, U.S. Polo Assn. also served as the Official Apparel Brand and Stadium Sponsor

Clean Air Metals Confirms Potential Major Extension at Escape Deposit Along 2.5 km Magnetic Trend4.9.2025 13:00:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / September 4, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to report that it has intersected over 50 m of magmatic sulphide mineralization in the Escape ultramafic conduit at a depth of 400 m (Image 1). The intersection was observed in core from drill hole EL25-001, located approximately 350 m from the current limits of the Escape Deposit ("Escape"). The target was the first of several coincident magnetic and electromagnetic anomalies to be drilled in the eastern half of the Escape conduit. The new intersection opens up 2.5 km of prospective geophysical targets and provides a critical new opportunity to expand the existing mineral inventory1 in the Thunder Bay North ("TBN") project, which compliments the Company's focus on advancing the project to potentially become a significant critical minerals producer of Cu, Pt, Pd and Ni. Assay results are expected to be available in the coming we

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye